Observed Pneumococcal Carriage Among Alaska Native Children Who Received Reduced-Dose Schedules of 13-Valent Pneumococcal Conjugate Vaccine Between 2010 and 2012-Reference-Cited by-同舟云学术

Observed Pneumococcal Carriage Among Alaska Native Children Who Received Reduced-Dose Schedules of 13-Valent Pneumococcal Conjugate Vaccine Between 2010 and 2012

Published:2017-11-14 Issue:9 Volume:66 Page:1478-1479
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Mosites Emily¹,Bruden Dana¹,Bruce Michael G¹,Hennessy Thomas¹,Gounder Prabhu¹

Affiliation:

1. Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/66/9/1478/24649486/cix1020.pdf

Reference9 articles.

1. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children—Advisory Committee on Immunization Practices (ACIP), 2010;Centers for Disease Control and Prevention (CDC);MMWR Morb Mortal Wkly Rep,2010

2. Pneumococcal vaccines. WHO position paper—2012: recommendations;World Health Organization;Vaccine,2012

3. The potential for reducing the number of pneumococcal conjugate vaccine doses while sustaining herd immunity in high-income countries;Flasche;PLoS Med,2015

4. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial;Silfverdal;Vaccine,2013

5. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study;Moore;Lancet Respir Med,2016